Lymphoma genetics

[1]  M. Davids,et al.  IGHV mutational status testing in chronic lymphocytic leukemia , 2017, American journal of hematology.

[2]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[3]  C. Copie-Bergman,et al.  Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study , 2016, Clinical Cancer Research.

[4]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[5]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[6]  L. Staudt,et al.  Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Advani,et al.  Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[8]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[9]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[10]  R. Foà,et al.  NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment , 2014, Leukemia & lymphoma.

[11]  R. Spang,et al.  A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. , 2014, Blood.

[12]  R. Spang,et al.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.

[13]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[14]  S. Barrans,et al.  Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B‐cell lymphoma and predict clinical outcome , 2012, British journal of haematology.

[15]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[16]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[17]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[18]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[19]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[20]  C. Messa,et al.  Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.

[21]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[22]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[23]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[24]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gascoyne,et al.  The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.

[27]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[28]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[29]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[30]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[33]  J. Kutok,et al.  Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. de Wolf‐Peeters,et al.  BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. , 2002, Blood.

[35]  M. Seto,et al.  Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-κB Signaling Pathway* , 2001, The Journal of Biological Chemistry.

[36]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[37]  E. Koonin,et al.  Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. , 2000, Molecular cell.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[40]  Bernell,et al.  Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B‐cell lymphoma: a study by FISH , 1998, British journal of haematology.

[41]  H. Hibshoosh,et al.  The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene , 1996 .

[42]  E. Jaffe,et al.  Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[44]  K. Offit,et al.  p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.

[45]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[46]  D. Weisenburger,et al.  Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. , 1992, Blood.

[47]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[48]  P. Nowell,et al.  Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. , 1984, Science.

[49]  J. Neffendorf,et al.  Ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[50]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[51]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[52]  Terry J. Hamblin,et al.  Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia , 1999 .